Percutaneous Patent Foramen Ovale Closure After Stroke

Oh-Hyun Lee, MD¹, and Jung-Sun Kim, MD, PhD²

¹Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin, Korea
²Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea

AUTHOR'S SUMMARY

Recent several randomized clinical trials have shown that percutaneous patent foramen ovale (PFO) closure reduced the stroke recurrence compared to the medical therapy alone in patients with a PFO-associated stroke. Nevertheless, optimal patient selection for PFO closure has not been clarified. In the current paper, we discuss the characteristics of PFO-associated strokes and discuss the recently published evidence and patient selection for PFO closure in patients with ischemic stroke.

ABSTRACT

Percutaneous patent foramen ovale (PFO) closure in patients with a prior PFO-associated stroke showed a risk reduction of the stroke recurrence compared to the medical therapy alone in recent several studies. Nevertheless, optimal patient selection for PFO closure has not been clarified. In this paper, we discuss the characteristics of PFO-associated strokes and discuss the recently published evidence and patient selection for PFO closure in patients with ischemic stroke. The lesions characteristics of PFO-associated stroke are associated with multiple scattered lesion, small sized cerebral cortical lesion, or posterior circulation. Overcoming the failure of early studies in CLOSURE I, PC, and RESPECT trials, PFO closure showed a significant reduction in recurrent stroke in recently published REDUCE, CLOSE, DEFENSE-PRO trials, and long-term follow-up data of RESPECT study. However, considering that PFO closure cannot completely prevent stroke recurrence and that complications including atrial fibrillation, we should be selectively performed in patients with high-risk PFO.

Keywords: Patent foramen ovale; Stroke; Paradoxical embolism

INTRODUCTION

Cryptogenic stroke refers to the development of cerebral embolism that is not attributed to large artery atherosclerosis, small vessel disease (lacunar infarcts), cardioembolism, or other determined cause. Cryptogenic strokes are thought to comprise approximately 25% of all ischemic strokes. Most cryptogenic strokes are thought to be an embolic stroke...
Data Sharing Statement
The data generated in this study is available from the corresponding author upon reasonable request.

Author Contributions
Conceptualization: Kim JS; Data Curation: Lee OH; Formal analysis: Lee OH; Funding acquisition: Kim JS; Investigation: Lee OH; Methodology: Lee OH, Kim JS; Project administration: Kim JS; Resources: Lee OH; Software: Lee OH; Supervision: Kim JS; Validation: Kim JS, Visualization: Lee OH, Kim JS; Writing- original draft: Lee OH; Writing- review & editing: Kim JS.

2) Patent Foramen Ovale (PFO) is a remnant of the fetal circulation characterized by a slit-like structure between the superior limb of the septum secundum on the right atrium side and the septum primum on the left atrium side. There is communication between the right and left atrium, particularly clinical situations that cause a sudden rise and fall in intrathoracic pressure, such as sneezing, coughing, or straining. Cohnheim et al.3) first reported on a potential causal relationship of a PFO and stroke in 1877. They postulated that a blood clot from the peripheral veins had migrated from the venous system into the systemic circulation through the PFO and blocked the cerebral artery. PFO was found a prevalence of 27.3% in an autopsy study of 965 normal hearts.4) Although PFO is incidentally detected for the majority of people, some PFOs provide a conduit for material such as thrombi. In this situation, percutaneous PFO closure provides a practical solution in carefully selected patients.

Therefore, it is very important to understand the characteristics of ischemic stroke caused by the PFO and selectively treat the PFO directly related to the occurrence of ischemic stroke. In this paper, we focused on the evidence for PFO closure, discuss which patients should be considered for percutaneous PFO closure.

CHARACTERISTICS OF PFO-ASSOCIATED STROKE

Recently, the term of cryptogenic stroke in the presence of PFO has changed into PFO-associated stroke.5) Stroke is the most common manifestation of paradoxical embolism. The process of blood clots entering arterial circulation through right-to-left shunt is essential to cause paradoxical embolism. Therefore, small sized cerebral cortical infarction lesions are observed in PFO-associated stroke, mainly because small blood clots are embolized into the brain through the PFO. In addition, Valsalva maneuver not only transiently increases the blood flow through the right-to-left shunt, but also relatively increases the blood flow to the posterior circulation system. Therefore, it is known that PFO-associate stroke during the Valsalva maneuver frequently occurs in the posterior circulation.6) In general, stroke patients caused by atherosclerosis occur in elderly patients, who have risk factors such as high blood pressure, diabetes mellitus, dyslipidemia, smoking history and prior transient ischemic attack (TIA) or stroke history. In contrast, patients with PFO-associated stroke do not have many of these risk factors because they are not caused by atherosclerosis.

PATIENT SELECTION

Because of the high prevalence of PFO (around 25%),7) physicians often have to decide whether PFO had a causal role for stroke, and whether PFO closure can reduce the recurrent event. However, optimal patient selection for percutaneous PFO closure has not been clarified.

Two scoring system have been proposed to assess the possibility of the PFO-associated strokes to date. A 10-point scale of a risk of paradoxical embolism (RoPE) score has been developed using the patient age, absence of vascular risk factors and brain imaging findings,
and the possibility of cerebral infarction caused by an PFO could be estimated. Those with a RoPE score greater than 6 are considered high risk with a PFO attributable fraction between 62–88% and Kaplan-Meier estimated stroke/TIA 2-year recurrence rates decreased from 20% (95% CI, 12–28%) in the lowest RoPE score stratum to 2% (95% CI, 0–4%) in the highest (Table 1). More recently, PFO-Associated Stroke Causal Likelihood (PASCAL) classification system also suggested. PASCAL scores combined the RoPE score with the presence or absence of high risk PFO features including large shunt and atrial septal aneurysm, to determine the likelihood that the PFO-associated stroke (Figure 1).

In the PASCAL scoring system, large shunt size was defined in the database as ≥20 bubbles in the left atrium on transesophageal echocardiography and atrial septal aneurysm was defined as ≥10 mm of excursion from midline. Among 1,383 patients for whom the PASCAL algorithm classified the PFO as having had a probable causal role in the stroke, there was a significant 90% relative reduction in the recurrent stroke over a median follow-up of 57 months. On the other hands, among 547 patients with stroke unrelated to the PFO, PFO closure was not associated with risk reduction of recurrent stroke but was associated with the higher rates of device-related atrial fibrillation. Patients classified as unlikely, possible, and probable using the PASCAL classification system had hazard ratios (HRs) 1.14 (95% CI, 0.53–2.46), 0.38 (95% CI, 0.22–0.65), and 0.10 (95% CI, 0.03–0.35), respectively. The 2-year absolute risk reduction was −0.7% (95% CI, −4.0–2.6%), 2.1% (95% CI, 0.6–3.6%), and 2.1%

**Table 1. PFO-attributable fraction and estimated 2-year risk of stroke/TIA by RoPE score**

| RoPE score | PFO-attributable fraction | Kaplan-Meier estimated 2-year stroke/TIA recurrence rate |
|------------|---------------------------|--------------------------------------------------------|
| 0–3        | 0 (0–4)                   | 20 (12–28)                                             |
| 4          | 38 (25–48)                | 12 (6–18)                                              |
| 5          | 34 (21–45)                | 7 (3–11)                                               |
| 6          | 62 (54–68)                | 8 (4–12)                                               |
| 7          | 72 (66–76)                | 6 (2–10)                                               |
| 8          | 84 (79–87)                | 6 (2–10)                                               |
| 9–10       | 88 (83–91)                | 2 (0–4)                                                |

Values are presented as % (95% confidence interval).

| RoPE score calculator | PASCAL classification system |
|-----------------------|------------------------------|
| **Patient characteristics** | **High RoPE score (≥7)** | **High-risk PFO feature (LS and/or ASA)** | **PFO-related stroke** |
| No history of hypertension | Absent | Absent | Unlikely |
| No history of diabetes | Absent | Present | Possible |
| No history of stroke or TIA | Present | Absent | |
| Nonsmoker | Present | Present | |
| Cortical infarct on imaging | Present | Present | |
| **Age, years** | **Total RoPE score** |
| 18–29 | 5 |
| 30–39 | 4 |
| 40–49 | 3 |
| 50–59 | 2 |
| 60–69 | 1 |
| ≥70 | 0 |
| **Total RoPE score** | **0–10** |

**Figure 1.** RoPE and PASCAL scoring system. ASA = atrial septal aneurysm; LS = large shunt; PASCAL = Patent Foramen Ovale-Associated Stroke Causal Likelihood; PFO = patent foramen ovale; RoPE = risk of paradoxical embolism; TIA = transient ischemic attack.
(95% CI, 0.9–3.4%) in the unlikely, possible, and probable PASCAL categories, respectively. Based on these results, physicians can apply the PASCAL scoring system to distinguish the patients whose PFO closure may be helpful from those who are unlikely among the patients aged 18 to 60 years.

Elderly patients over 60 years excluded from most of the randomized trials. However, previous study has shown that there is a relationship between older age and risk of recurrent stroke in patients with PFO. Recently, a multicenter study was published to evaluate the early- and long-term outcomes of percutaneous PFO closure in elderly (>60 years) patients with PFO-associated strokes. The study included the 388 and 883 patients with PFO closure at age over 60 (mean 67 years) and no more than 60 (mean 44 years), respectively. Patients over the age of 60 not only had a high burden on cardiovascular risk factors but also had a high incidence of large shunt and atrial septal aneurysm. PFO closure was safely performed in elderly patients, and the incidence of thromboembolism was relatively low during follow-up. However, compared to younger patients, the risk of stroke recurrence was higher in elderly patients.

As the patients get older, the incidence of atrial fibrillation increases rapidly. Therefore, extended rhythm monitoring through implantable loop recorders is important in elderly patients before considering PFO closure in patients who have experienced strokes over the age of 65. Nevertheless, the beneficial effect of PFO closure has been identified in selected patients through several observation studies to date. The clinical evidence of the potential benefit of PFO closure has limited in elderly patients and needs to be investigated with further clinical studies.

EVIDENCE FOR PERCUTANEOUS PFO CLOSURE

Six randomized clinical trials comparing the recurrent rate of ischemic stroke after percutaneous PFO closure compared to the medical treatment in patients with cryptogenic stroke have been published to date (Table 2). Initial 3 studies (CLOSURE I, PC, RESPECT) in 2012 and 2013 failed to show a benefit of PFO closure with an excess of complications in the interventional arm. The causes of these failure are as follow: inadequate patient selection (large number of patients with TIAs), a high rate of procedural failure, limited follow-up period and inadequate study design.

However, as treated analyses in the pooled analysis of individual participant data from previous 3 randomized trials produced that percutaneous PFO closure showed the significant reduction of recurrent strokes than medical therapy. Furthermore, meta-analysis of randomized trials have reported that percutaneous PFO closure may be beneficial in reducing the risk of recurrent events when compared to medical treatment in patients with cryptogenic stroke, especially with Amplatzer device. Based on these results, 3 additional studies (REDUCE, CLOSE and DEFENSE-PFO) were conducted and published along with the results of long-term follow-up data of RESPECT trial. In the 3 new trials, they included the patients with index strokes more likely secondary to paradoxical embolism or higher-risk PFOs. REDUCE, CLOSE and DEFENSE-PFO trials showed a significant reduction in recurrent stroke in the PFO closure group. In addition, RESPECT with longer-term results (median follow-up duration of 5.9 years) also showed the increasing benefit over time in the patients treated with percutaneous PFO closure. The most recently published DEFENSE-PFO study was conducted in South Korea, and followed up for 2.8 years in 120 patients with cryptogenic
stroke and high-risk PFO (PFO with atrial septal aneurysm, hypermobility, PFO size ≥2 mm). No stroke occurred in the closure group at all, but in 12.9% of the medical treatment group. During the follow-up period, magnetic resonance imaging was performed after 6 months, and a symptomatic ischemic stroke was more observed in the medical therapy group, but was not statistically significant (closure vs. medical therapy; 8.8% vs. 18.4%, p=0.24).

**FUTURE PERSPECTIVES**

Through the discrepancy of early and later studies results, we learned a group of patients with a high risk of recurrence of paradoxical embolism. By excluding other identified causes of stroke, we can reduce the recurrence of ischemic stroke through procedures in patients with PFO. Strict selection of patients for PFO closure can ensure that percutaneous PFO closure in guidelines can be changed to what is recommended as first-line therapy.

There is a lack of data comparing the effects of PFO closure or antiplatelet agents and oral anticoagulants to prevent recurrent stroke. The CLOSURE trial was the only one in which patients were randomized to PFO closure, oral anticoagulation or antiplatelet therapy. However, the study was underpowered as many patients had contraindications to oral anticoagulation. The CLOSURE trial showed a nonsignificant 56% risk reduction in the recurrent stroke in patients treated to oral anticoagulants compared with patients with antiplatelet therapy. Unfortunately, none of the recently published NAVIGATE-ESUS trial comparing aspirin 100 mg and rivaroxaban 15 mg, and RE-SPECT ESUS trial comparing...
110 mg or 150 mg of dabigatran in patients with ESUS demonstrated the superiority of oral anticoagulants in preventing recurrent stroke against aspirin. Major bleeding increased in Rivaroxaban group, but dabigatran had no significant difference from aspirin. In the future, a well-designed study comparing PFO and oral anticoagulation through randomized trial is needed.

Additional studies will be needed on longer than 10 years of long-term clinical data related to the occurrence of AF and recurrence of stroke, and the optimal regimen and duration of antiplatelet agents after PFO closure. Optimal patient selection for PFO closure may require further research on the ethnic difference in thrombogenicity and response to oral antithrombotic therapy. In the distant future, we will also have to discuss PFO closure for primary prevention in some selected patients.

CONCLUSIONS

Percutaneous PFO closure in patients between the ages of 18 and 60 with a prior PFO-associated stroke reduced the stroke recurrence compared to the antiplatelet therapy alone. Considering that PFO closure cannot completely prevent stroke recurrence and that complications including atrial fibrillation, we should be selectively performed in patients with high-risk PFO.

REFERENCES

1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.

2. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13:429-38.

3. Cohnheim J. Thrombosis and embolism. In: Lectures on General Pathology: A Handbook for Physicians and Students. Berlin: August Hirschwald; 1877. p.134.

4. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59:17-20.

5. Elgendy AI, Saver JL, Amin Z, et al. Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale–associated stroke. JAMA Neurol 2020;77:878-86.

6. Kim BJ, Sohn H, Sun BJ, et al. Imaging characteristics of ischemic strokes related to patent foramen ovale. Stroke 2013;44:3350-6.

7. Koutroulou I, Tsivgoulis G, Tsilikakis D, Karacostas D, Grigoriadis N, Karapanayiotides T. Epidemiology of patent foramen ovale in general population and in stroke patients: a narrative review. Front Neurol 2020;11:281.

8. Kent DM, Ruthazer R, Weinam C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013;81:619-25.

9. Kent DM, Saver JL, Kasner SE, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA 2021;326:2277-86.
10. Alperi A, Guedeney P, Hotlick E, et al. Transcatheter closure of patent foramen ovale in older patients with cryptogenic thromboembolic events. Circ Cardiovasc Interv 2022;15:e011652.

11. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013;368:1092-100.

12. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:991-9.

13. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013;368:1083-91.

14. Spencer FA, Lopes LC, Kennedy SA, Guyatt G. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open 2014;4:e004282.

15. Kent DM, Dahabreh II, Ruthazer R, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol 2016;67:90747.

16. Khan AR, Bin Abdulhak AA, Sheikh MA, et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. JACC Cardiovasc Interv 2013;6:1316-23.

17. Rengifo-Moreno P, Palacios IF, Junpaparp P, Witzke CF, Morris DL, Romero-Corral A. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2013;34:3342-52.

18. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol 2018;71:2335-42.

19. Mas JL, Derumeaux G, Guillot B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017;377:1011-21.

20. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017;377:1033-42.

21. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017;377:1022-32.

22. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-201.

23. Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019;380:1906-17.

24. Kim HK, Tantry US, Park HW, et al. Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences. Korean Circ J 2021;51:202-21.

25. Cho H, Kang J, Kim HS, Park KW. Ethnic differences in oral antithrombotic therapy. Korean Circ J 2020;50:645-57.